BindingDB logo
myBDB logout

254 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28274635 381 Identification of novel TACE inhibitors compatible with topical application.EBI Nestl� Skin Health R&D
27966948 86 Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.EBI Pharmaceutical Company Limited
28337319 28 Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.EBI Universit£ di Pisa
27914947 11 Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).EBI University of Florence
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Company Limited
27452283 241 Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.EBI Jadavpur University
27038494 18 Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.EBI Fudan University
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26638045 58 Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.EBI UiT The Arctic University of Norway
26346367 77 Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.EBI Nanjing University
26386821 15 Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.EBI Shandong University
26263024 47 N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI Universit£ di Pisa
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25921268 36 New matrix metalloproteinase inhibitors based on¿-fluorinateda-aminocarboxylic anda-aminohydroxamic acids.EBI Westf£lische Wilhelms-Universit£t M£nster
25438884 11 A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.EBI University Medical Center Groningen
25265401 38 Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI Universidad CEU San Pablo
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.EBI Takeda Pharmaceutical Company Ltd
24028490 46 O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.EBI University of Notre Dame
23375794 220 Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.EBI Nanjing University of Chinese Medicine
23353736 41 Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).EBI Second Military Medical University
23287054 46 Sulphonamides: Deserving class as MMP inhibitors?EBI Indian Institute of Technology (BHU)
23458498 24 Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI Universit£ del Piemonte Orientale"Amedeo Avogadro"
23246356 52 MMP inhibition by barbiturate homodimers.EBI Trinity College
17275314 701 Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI Pomona College
21669521 44 Selective non zinc binding inhibitors of MMP13.EBI AstraZeneca
23134659 74 Design and synthesis of procollagen C-proteinase inhibitors.EBI FibroGen Inc.
21413808 170 Synopsis of some recent tactical application of bioisosteres in drug design.EBI Bristol-Myers Squibb Pharmaceutical Research and Development
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
21413800 56 A one-pot synthesis and biological activity of ageladine A and analogues.EBI Macquarie University
23149299 50 Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.EBI Universit£ degli Studi di Bari Aldo Moro
22540974 67 A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.EBI University Hospital M£nster
22248361 24 Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.EBI Trinity College
22737278 44 Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI TBA
22658537 76 Natural products as a gold mine for selective matrix metalloproteinases inhibitors.EBI East China University of Science and Technology
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
24900330 47 The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design.EBI TBA
22342144 72 Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI PanThera Biopharma, LLC
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19635666 119 Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI Incyte Corporation
19128977 4 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.EBI UNED
19095454 63 Current perspective of TACE inhibitors: a review.EBI The M. S. University of Baroda
17981034 51 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.EBI Johnson& Johnson Pharmaceutical Research and Development
17980583 46 Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).EBI Johnson& Johnson Pharmaceutical Research and Development
18086526 85 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.EBI Johnson& Johnson Pharmaceutical Research and Development
18257543 16 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI The Hebrew University of Jerusalem
18251495 69 Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
18029173 316 Synthesis and evaluation of novel heterocyclic MMP inhibitors.EBI North Dakota State University
17956082 86 Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.EBI University Hospital of the Westf£lische Wilhelms-Universit£t M£nster
17127067 21 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI Instituto Superior T£cnico
17276072 95 Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.EBI Universit£ di Pisa
15857146 30 C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.EBI University Hospital of the Westf£lische Wilhelms-Universit£t
15713379 40 N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI Universit£ degli Studi di Pisa
15582436 7 N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.EBI Sejong University
15214773 76 Fragment-based drug discovery.EBI Sunesis Pharmaceuticals Inc.
15139760 110 Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.EBI The Hebrew University of Jerusalem
12930146 170 Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.EBI Institut de Recherches Servier
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
12773041 119 Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11831904 172 New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.EBI Nippon Organon K.K.
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
11472202 143 Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI TBA
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
10649971 180 Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI Parke-Davis Pharmaceutical Research
10579818 162 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
9888835 42 Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI Procter and Gamble Pharmaceuticals
9733482 31 Discovery of potent, achiral matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
14980648 16 New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.EBI Universit£ des Sciences et Technologies de Lille
15177439 96 Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc.
11327577 86 Heterocycle-based MMP inhibitors with P2' substituents.EBI Procter and Gamble Pharmaceuticals
11677139 92 The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.EBI Wyeth-Ayerst Research
11206468 24 Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.EBI Wyeth-Ayerst Research
11206467 44 The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.EBI Wyeth-Ayerst Research
11514167 88 The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.EBI Wyeth-Ayerst Research
11378378 34 Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.EBI Celltech Chiroscience Ltd
10340614 20 Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.EBI The DuPont Pharmaceutical Co.
10450979 4 Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.EBI University of Cambridge
10397503 40 Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.EBI Universit£ de Montr£al
9873598 39 The synthesis and biological activity of a novel series of diazepine MMP inhibitors.EBI Wyeth-Ayerst Research
22386984 67 In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI Colosseum Combinatorial Chemistry Centre for Technology (C4T SCarl)
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22118188 50 A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.EBI University Hospital M£nster
22153941 140 Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI AstraZeneca
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
22153340 37 Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).EBI Pfizer Inc.
22082667 67 Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI Microbiotix, Inc.
21851064 3 Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.EBI Indiana University School of Medicine
21925881 60 Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.EBI Johnson& Johnson Pharmaceutical Research& Development
21548582 57 Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.EBI University of Illinois at Chicago
21866961 28 Selective water-soluble gelatinase inhibitor prodrugs.EBI University of Notre Dame
21764590 98 N-substituted homopiperazine barbiturates as gelatinase inhibitors.EBI Trinity College
20726512 282 Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI Pfizer Inc.
21514700 56 Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI Universit£ di Pisa
21536437 219 Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI AstraZeneca
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21507637 102 MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI Pfizer Inc.
21493063 67 MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI Pfizer Inc.
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21417219 179 Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.EBI Central Pharmaceutical Research Institute
24900296 38 Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI TBA
21078557 34 Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.EBI Yonsei University
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20529685 70 MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20529684 112 Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20053563 10 Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.EBI Wonkwang University Sanbon Medical Center
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19775099 184 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI Universit£ di Pisa
19625186 59 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.EBI Wyeth Research
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
19606871 124 N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI Universit£ di Pisa
 2 Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinasesEBI TBA
 39 Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moietyEBI TBA
 97 Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI TBA
 30 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimicsEBI TBA
 17 Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)EBI TBA
 44 Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistryEBI TBA
 47 Hydroxamate inhibitors of human gelatinase B (92 kDa)EBI TBA
 5 Inhibition of metalloproteinase by futoenone derivativesEBI TBA
19457660 90 Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI Incyte Corporation
19053764 101 Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI Instituto Superior Técnico
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18782669 90 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI Université de Reims-Champagne-Ardenne
18442906 40 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.EBI North Dakota State University
18364257 16 Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.EBI The Scripps Research Institute
17719700 39 Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI Università G. d'Annunzio
17623656 34 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI Pfizer Global Research and Development
18083558 112 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.EBI Johnson & Johnson Pharmaceutical Research and Development
18068976 132 Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI Incyte Corporation
18036818 157 Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI Incyte Corporation
18029177 57 A novel series of highly selective inhibitors of MMP-3.EBI Pfizer Global Research and Development
17936631 25 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.EBI Yonsei University
17591762 102 Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI Pfizer Global Research and Development
17583333 4 Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.EBI Università di Bari
17512742 32 Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI Université de Reims-Champagne-Ardenne
17368021 55 Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17256836 84 Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI Incyte Corporation
17188863 107 Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17088065 106 alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI Università "G. d'Annunzio"
17064892 123 Identification of potent and selective TACE inhibitors via the S1 pocket.EBI Wyeth Research
17027261 153 Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16723229 108 Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI Wyeth Research
16632358 68 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.EBI Johnson & Johnson Pharmaceutical Research and Development
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16420030 38 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI Chinese Academy of Sciences
16392792 29 Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI Aventis Pharma Deutschland GmbH
16289878 35 Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16107143 33 A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.EBI North Dakota State University
16084720 83 Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.EBI Wyeth Research
16002291 24 Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.EBI Pfizer Global Research and Development
15953722 56 Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI Pfizer Global Research and Development
15908214 95 Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15837315 13 A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI Università degli Studi di Pisa
15686921 55 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI Pharmaceutical Research Institute
15566296 142 Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.EBI Wyeth Research
15357971 228 Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15341955 52 Synthesis and evaluation of novel oxazoline MMP inhibitors.EBI North Dakota State University
15324896 71 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI Pfizer Global Research and Development
15125955 84 Reverse hydroxamate-based selective TACE inhibitors.EBI Kaken Pharmaceutical Co., Ltd
15055993 30 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.EBI Hokkaido Collaboration Center N-21
15006405 20 Synthesis and biological activity of selective azasugar-based TACE inhibitors.EBI Organon K.K.
14711305 26 Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI University of Athens
14684295 109 Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI Chinese Academy of Sciences
14643313 132 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14643312 39 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Global Research and Development
12877587 6 Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.EBI National Cardiovascular Center Research Institute
12873518 81 Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.EBI Wyeth Research
12873505 20 Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12873504 36 Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12798337 6 Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI Indiana University School of Medicine
12781190 113 Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12781187 15 Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Organon K.K.
12723945 167 Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12668018 138 Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.EBI Wyeth-Ayerst Research
12657268 13 Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Company
12270165 80 Benzodiazepine inhibitors of the MMPs and TACE.EBI Wyeth Research
11958997 53 Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.EBI University of Bielefeld
11934588 69 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.EBI Wyeth-Ayerst Research
11934587 19 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.EBI Wyeth-Ayerst Research
11844676 48 Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.EBI Organon K.K.
11831905 33 New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.EBI Organon K.K.
11754593 148 Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI Abbott Laboratories
11738583 45 Potent P1' biphenylmethyl substituted aggrecanase inhibitors.EBI Bristol-Myers Squibb Pharma Company
11708926 84 Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI GlaxoSmithKline
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11585439 44 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.EBI The DuPont Pharmaceuticals Company
11563922 147 Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI Universität Bielefeld
11543676 45 Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.EBI Université de Montréal
11543675 104 N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.EBI Université de Montréal
11514157 48 N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.EBI GlaxoSmithKline Research and Development
11412980 48 Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI Abbott Laboratories
11354379 37 Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.EBI Pfizer Global Research & Development
11327602 58 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI Roche Research Center
11229774 40 Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI Pfizer Global Research and Development
11229773 73 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI Pfizer Global Research and Development
11212095 65 General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.EBI Institut de Recherches Servier
10882354 19 Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.EBI Pfizer Inc.
10794702 340 Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.EBI Università degli Studi
10669564 189 Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
10560745 46 Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.EBI SmithKline Beecham Pharmaceuticals
10411481 144 Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI CEA
10360755 17 P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.EBI DuPont Pharmaceuticals Company
10346925 40 Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.EBI Shionogi & Company, Ltd.
10212120 34 Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.EBI Affymax Research Institute
9871728 27 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.EBI Wyeth-Ayerst Research
9871727 58 Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.EBI Affymax Research Institute
9871551 48 Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.EBI DuPont Merck Pharmaceutical Company
9632351 36 Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.EBI Affymax Research Institute
9599226 25 Macrocyclic amino carboxylates as selective MMP-8 inhibitors.EBI The DuPont Merck Pharmaceutical Co.
9599225 9 Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.EBI The DuPont Merck Pharmaceutical Company
9548812 67 Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI Kanebo Ltd.
9484512 130 Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI Shionogi & Co., Ltd.
9457244 189 Matrix metalloproteinase inhibitors: a structure-activity study.EBI Glycomed, Inc.
9191969 31 Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.EBI Institut de Recherche Servier
8277511 57 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.EBI Merck Research Laboratories
8126708 113 Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.EBI Glaxo Incorporated Research Institute
28408220 55 First insight into structure-activity relationships of selective meprin? inhibitors.EBI Fraunhofer Institute for Cell Therapy and Immunology IZI
28653849 67 Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.EBI Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.
21827363 20 Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-a converting enzyme (TACE/ADAM-17).BDB China Pharmaceutical University
21406033 4 The evaluation of inhibitive effectiveness of the tumour necrosis factor-a converting enzyme selective inhibitors by HPLC.BDB Huazhong University of Science and Technology
20817735 24 Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.BDB Commissariat à l'Energie Atomique
20308072 8 Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.BDB Sanford-Burnham Medical Research Institute
22689580 90 Simple Pseudo-dipeptides with a P2' Glutamate: A NOVEL INHIBITOR FAMILY OF MATRIX METALLOPROTEASES AND OTHER METZINCINS.BDB Commissariat á l'Energie Atomique
19422229 125 Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.BDB Novartis
18221310 180 Rhodanine derivatives as selective protease inhibitors against bacterial toxins.BDB Burnham Institute for Medical Research
19173605 18 Extra Binding Region Induced by Non-Zinc Chelating Inhibitors into the S(1)' Subsite of Matrix Metalloproteinase 8 (MMP-8) (dagger).BDB Universita degli Studi
18234496 12 Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).BDB Bristol-Myers Squibb Company
18054488 24 Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.BDB Vertex Pharmaceuticals
17289381 30 Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.BDB Vertex Pharmaceuticals
14718605 8 Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.BDB Wyeth Research
9258358 65 Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.BDB Novartis Pharmaceuticals
16220987 133 Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.BDB Pfizer
12217351 135 Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.BDB Universita degli Studi di Firenze
15163180 40 Sultam hydroxamates as novel matrix metalloproteinase inhibitors.BDB Bristol-Myers Squibb Company
11020282 512 Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.BDB Universita degli Studi